Regeneron Pharmaceuticals, Inc. nears a key earnings report after a strong JPM Healthcare update. Click here to find out why ...

The story around Regeneron is shifting, and one big player just made it official.

Sanofi has said it will press ahead with regulatory filings for atopic dermatitis (AD) candidate amlitelimab after reporting ...

The company will prioritise investment for in-house innovation over large M&A deals, bucking the trend across pharma.

Longleaf Partners, managed by Southeastern Asset Management, released its fourth-quarter 2025 investor letter. A copy of the ...

The mixed data from the Phase III COAST 2 trial follows an underwhelming data drop from COAST 1 in September that Leerink ...

Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U ...

Sanofi has reported mixed phase 3 data on amlitelimab, further muddying the prospec | Sanofi has reported mixed phase 3 data ...

The patent for Dupixent, called the "miracle atopic dermatitis treatment," will expire around 2031. Dupixent was co-developed by French drugmaker Sanofi and U.S. biotech Regeneron and posted $14.1 ...

Among other things, we talked about President Trump’s “most-favored nations” policy on drug pricing and why Regeneron is the ...